DIFFUSION OF DILUTE FLUORESCENT MOLECULES IN NANOFABRICATED CHANNELS

稀荧光分子在纳米通道中的扩散

• 批准号: 6349439
• 负责人: SAMUEL T HESS
• 金额: $ 0.04万
• 依托单位: CORNELL UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2000
• 资助国家: 美国
• 起止时间: 2000-09-01 至 2001-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6349439
• 关键词: animal tissue; bioengineering /biomedical engineering; biological products; biomedical resource; lasers

We propose to evaluate two-photon microscopy of BPD-MA to study subcellular localization under a variety of conditions. Benzoporphyrin Derivative is a second-generation photosensitizing compound currently undergoing phase II clinical trials for use in treating psoriasis, age-related macular degeneration as well as cutaneous oncology. Previous research has demonstrated that this drug is a potent sensitizer, with efficacy in cell killing demonstrated at concentrations below 200 ng/ml. Its primary subcellular target is believed to the mitochondria, where it has been demonstrated that BPD-MA can photodynamically uncouple oxidative phosphorylation in the isolated rat mitochondria. Our initial experiments have sought to optimize two-photon microscopy for observation of this drug. The two-photon cross section of BPD-MA in a liposomal preparation has recently been measured from 820-980 nm. Having measured the cross section, we will be able to evaluate a detection threshold that will then be ve rified in adherent cell culture. Organelle localization studies have been outlined are expected to proceed in the near future.

我们建议评估 BPD-MA 的双光子显微镜来研究 多种条件下的亚细胞定位。 苯并卟啉衍生物是第二代光敏剂 该化合物目前正在进行 II 期临床试验，用于 治疗牛皮癣、年龄相关性黄斑变性以及 皮肤肿瘤学。 先前的研究表明，这种药物 是一种有效的敏化剂，具有杀死细胞的功效 浓度低于 200 ng/ml。 其主要亚细胞靶标是 相信线粒体，已经证明 BPD-MA 可以光动力解偶联氧化磷酸化 分离的大鼠线粒体。 我们最初的实验试图 优化双光子显微镜以观察该药物。 这 脂质体制剂中 BPD-MA 的双光子横截面具有 最近在 820-980 nm 范围内进行了测量。 测量完十字架后 部分，我们将能够评估检测阈值 然后在贴壁细胞培养中进行验证。 细胞器定位 已概述的研究预计将在不久的将来进行。